The Interplay of Autophagy and Oxidative Stress in the Kidney: What Do We Know?

被引:0
作者
Guo, Haihua [1 ]
Bechtel-Walz, Wibke [1 ]
机构
[1] Univ Freiburg, Fac Med, Med Ctr, Dept Med,Renal Div, Freiburg, Germany
关键词
Autophagy; Oxidative stress; Reactive oxygen species; Acute kidney injury; Chronic kidney disease; ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-ALDOSTERONE SYSTEM; REGULATE AUTOPHAGY; INTERACTING PROTEIN; SIGNALING PATHWAYS; PODOCYTE AUTOPHAGY; PROXIMAL TUBULES; HEME OXYGENASE; NADPH OXIDASES; EMERGING ROLE;
D O I
10.1159/000531290
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Autophagy, as an indispensable metabolism, plays pivotal roles in maintaining intracellular homeostasis. Nutritional stress, amino acid deficiency, oxidative stress, and hypoxia can trigger its initiation. Oxidative stress in the kidney activates essential signal molecules, like mammalian target of rapamycin (mTOR), adenosine monophosphate-activated protein kinase (AMPK), and silent mating-type information regulation 2 homolog-1 (SIRT1), to stimulate autophagy, ultimately leading to degradation of intracellular oxidative substances and damaged organelles. Growing evidence suggests that autophagy protects the kidney from oxidative stress during acute ischemic kidney injury, chronic kidney disease, and even aging. Summary: This review emphasizes the cross talk between reactive oxygen species (ROS) signaling pathways and autophagy during renal homeostasis and chronic kidney disease according to the current latest research and provides therapeutic targets during kidney disorders by adjusting autophagy and suppressing oxidative stress. Key Messages: ROS arise through an imbalance of oxidation and antioxidant defense mechanisms, leading to impaired cellular and organ function. Targeting the overproduction of ROS and reactive nitrogen species, reducing the antioxidant enzyme activity and the recovery of the prooxidative-antioxidative balance provide novel therapeutic regimens to contribute to recovery in acute and chronic renal failure. Although, in recent years, great progress has been made in understanding the molecular mechanisms of oxidative stress and autophagy in acute and chronic renal failure, the focus on clinical therapies is still in its infancy. The growing number of studies on the interactive mechanisms of oxidative stress-mediated autophagy will be of great importance for the future treatment and prevention of kidney diseases.
引用
收藏
页码:627 / 641
页数:15
相关论文
共 50 条
  • [41] The Role of Oxidative Stress in Kidney Injury
    Piko, Nejc
    Bevc, Sebastjan
    Hojs, Radovan
    Ekart, Robert
    ANTIOXIDANTS, 2023, 12 (09)
  • [42] Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella, Mark A.
    Shirali, Anushree C.
    KIDNEY INTERNATIONAL, 2020, 97 (01) : 62 - 74
  • [43] Anesthetic Agents and Neuronal Autophagy. What We Know and What We Don't
    Xu, Lili
    Shen, Jianjun
    McQuillan, Patrick M.
    Hu, Zhiyong
    CURRENT MEDICINAL CHEMISTRY, 2018, 25 (08) : 908 - 916
  • [44] Chronic Kidney Disease of Unknown Etiology in India: What Do We Know and Where We Need to Go
    John, Oommen
    Gummudi, Balaji
    Jha, Anubhuti
    Gopalakrishnan, Natarajan
    Kalra, Om P.
    Kaur, Prabhdeep
    Kher, Vijay
    Kumar, Vivek
    Machiraju, Ravi Shankar
    Osborne, Nicolas
    Palo, Subrata Kumar
    Parameswaran, Sreejith
    Pati, Sanghamitra
    Prasad, Narayan
    Rathore, Vinay
    Rajapurkar, Mohan M.
    Sahay, Manisha
    Tatapudi, Ravi Raju
    Thakur, Jarnail S.
    Venugopal, Vidhya
    Jha, Vivekanand
    KIDNEY INTERNATIONAL REPORTS, 2021, 6 (11): : 2743 - 2751
  • [45] Fibroblast growth factor-23: what we know, what we don't know, and what we need to know
    Kovesdy, Csaba P.
    Quarles, Leigh Darryl
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (09) : 2228 - 2236
  • [46] Preventing Harm During Treatment of Acute Kidney Injury: What Do We Really Know?
    Hofmann, R. Michael
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2012, 19 (03) : 142 - 148
  • [47] The side effects of phototherapy for neonatal jaundice: what do we know? What should we do?
    Xiong, Tao
    Qu, Yi
    Cambier, Stephanie
    Mu, Dezhi
    EUROPEAN JOURNAL OF PEDIATRICS, 2011, 170 (10) : 1247 - 1255
  • [48] What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino, Mario
    Galassi, Andrea
    Apetrii, Mugurel
    Covic, Adrian
    JOURNAL OF NEPHROLOGY, 2011, 24 (06) : 696 - 706
  • [49] FELINE CKD Pathophysiology and risk factors - what do we know?
    Reynolds, Brice S.
    Lefebvre, Herve P.
    JOURNAL OF FELINE MEDICINE AND SURGERY, 2013, 15 (S1) : 3 - 14
  • [50] Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?
    Mazzaferro, Sandro
    Cianciolo, Giuseppe
    De Pascalis, Antonio
    Guglielmo, Chiara
    Torres, Pablo A. Urena
    Bover, Jordi
    Tartaglione, Lida
    Pasquali, Marzia
    La Manna, Gaetano
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (12) : 2092 - 2100